Invitation to subscribe in
Spermosens AB’s
Unit Rights Issue
Subscription period: 9 – 23 January 2023
Please note that certain banks may close for subscription as early as Thursday, the 19th of January
đŁ Join CEO Ulrik Nilsson for a live presentation of the company with Q&A in a Teams Meeting on Monday, the 16th at 5pm, OR Tuesday, the 17th at 4pm. Click here to SIGN UP. đŁ
Message from CEO Ulrik Nilsson:
“For the first time, it will be possible to measure whether a man is actually fertile.”
“Current diagnostics assess the physical characteristics of sperms; their count, how they move and what they look like, unfortunately these factors do not always determine whether a man is fertile.
Spermosensâ first patented product is based on biotechnology and electrochemistry and analyses the binding capacity between sperm and the egg cell, indicating the chance for natural fertilisation.
The global IVF market reached USD 22 billion in 2021 and is projected to grow at a CAGR of six per cent until 2030 (GVR, 2020). With over 3 million annual treatments, we estimate the sales potential for our first product, to over $600 million.
Sales for research purposes are due to commence this year. This is an important stepping stone for us in our efforts to reach the market. We will gain awareness, valuable insight into how IVF specialists perceive our products and, at the same time, we collect research data.
We have signed letters of intent for future research sales to selected customers and look forward to delivering our products. As we move towards certification for diagnostic use, we plan to increase our commercial activities.
Spermosens is working with two manufacturers for future production. OIM Sweden AB for the JUNO-Checked instrument and FlexMedical Solutions Ltd for the JUNO-Checked cassette. A large part of the proceeds from the current unit issue will be directed to preparation of our technology for full scale commercial launch.
Sales for research purposes are due to commence this year. This is an important stepping stone for us in our efforts to reach the market. We will gain awareness, valuable insight into how IVF specialists perceive our products and, at the same time, we collect research data.
We have signed letters of intent for future research sales to selected customers and look forward to delivering our products. As we move towards certification for diagnostic use, we plan to increase our commercial activities.
Spermosens is working with two manufacturers for future production. OIM Sweden AB for the JUNO-Checked instrument and FlexMedical Solutions Ltd for the JUNO-Checked cassette. A large part of the proceeds from the current unit issue will be directed to preparation of our technology for full scale commercial launch.
The promise of our technology is to help physicians choose the appropriate treatment, thereby improving the conditions for individualized treatment with assisted reproductive technology (ART) and with that, we are well on our way to become a technology- and market leader within male fertility diagnostics and treatment.
I am strongly committed to Spermosens’ vision to improve the quality of life for all those affected by infertility and involuntary childlessness.
Together with the team, I look forward to continuing the work of developing and successfully launching our products. Our journey is important, the potential is compelling, and we have come a long way. This rights issue is an important next step, and you are invited.”
The offer in summary
- Subscription period: 9 – 23 January 2023
- Subscription price: 0.84 SEK per share
- Issue volume: the offer comprises a maximum of 29,077,889 new shares, corresponding in total to approximately SEK 24.4 million. The offer includes up to 29,077,889 warrants of series TO2, allocated 1:1 and free of charge.
- Preferential subscription rights: anyone registered as a shareholder in the share register kept by Euroclear Sweden AB, on behalf of Spermosen, on the record date of 4 January 2023, has preferential subscription rights to Units in the Rights Issue in relation to previous holdings of shares (12 units for each 5 shares).
Commitments
Spermosens has received pre-subscription and underwriting commitments from a consortium of guarantors totalling approximately SEK 18.0 million, corresponding to approximately 73.6 percent of the total issue volume, covering up to 90% of the issue. Subscription commitments include pre-subscription from existing owners, including the Board of Directors and management, total approximately SEK 1.0 million (approximately 4.0 percent of the issue volume).
More Information
You can find more information on Spermosens Investor Landing Page.
How to subscribe?
Follow instructions from your bank. Or, if you want to subscribe without rights, then you can use the following subscription form:
Subscription Form – Online
Subscription Form – Swe
Subscription Form – Eng
